Dyskinesias in Parkinson's disease: views from positron emission tomography studies. (28th January 2014)

• Record Type: Journal Article
• Authors: Niccolini, F.; Loane, C.; Politis, M.
• Is Part Of: European journal of neurology. Volume 21:Number 5(2014:May)
• Page Start: 694
• Page End: e43
• Publication Date: 2014-01-28
• Subjects: Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.12362
• Languages: English
• ISSNs: 1351-5101

Abstract

<abstract abstract-type="main" id="ene12362-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Levodopa‐induced dyskinesias (LIDs) and graft‐induced dyskinesias (GIDs) are serious and common complications of Parkinson's disease (PD) management following chronic treatment with levodopa or intrastriatal transplantation with dopamine‐rich foetal ventral mesencephalic tissue, respectively. Positron emission tomography (PET) molecular imaging provides a powerful <italic>in vivo</italic> tool that has been employed over the past 20 years for the elucidation of mechanisms underlying the development of LIDs and GIDs in PD patients. PET used together with radioligands tagging molecular targets has allowed the functional investigation of several systems in the brain including the dopaminergic, serotonergic, glutamatergic, opioid, endocannabinoid, noradrenergic and cholinergic systems. In this article the role of PET imaging in unveiling pathophysiological mechanisms underlying the development of LIDs and GIDs in PD patients is reviewed.</p> </abstract>